Metabolomics of sebum reveals lipid dysregulation in Parkinson’s disease

Eleanor Sinclair; Drupad K. Trivedi; Depanjan Sarkar; Caitlin Walton-Doyle; Joy Milne; Tilo Kunath; Anouk M. Rijs; Rob M. A. De Bie; Royston Goodacre; Monty Silverdale; Perdita Barran

doi:10.1038/s41467-021-21669-4

Metabolomics of sebum reveals lipid dysregulation in Parkinson’s disease

Eleanor Sinclair, Drupad K. Trivedi, Depanjan Sarkar, Caitlin Walton-Doyle, Joy Milne, Tilo Kunath, Anouk M. Rijs, Rob M. A. De Bie, Royston Goodacre, Monty Silverdale, Perdita Barran

Research output: Contribution to journal › Article › peer-review

Abstract / Description of output

Parkinson’s disease (PD) is a progressive neurodegenerative disorder, which is characterised by degeneration of distinct neuronal populations, including dopaminergic neurons of the substantia nigra. Here, we use a metabolomics profiling approach to identify changes to lipids in PD observed in sebum, a non-invasively available biofluid. We used liquid chromatography mass spectrometry (LC-MS) to analyse 274 samples from participants (80 drug naïve PD,138 medicated PD and 56 well matched control subjects) and detected metabolites that could predict PD phenotype. Pathway enrichment analysis shows alterations in lipid metabolism related to the carnitine shuttle, sphingolipid metabolism, arachidonic acid metabolism and fatty acid biosynthesis. This study shows sebum can be used to identify potential biomarkers for PD.

Original language	English
Article number	1592
Number of pages	9
Journal	Nature Communications
Volume	12
Issue number	1
DOIs	https://doi.org/10.1038/s41467-021-21669-4
Publication status	Published - 11 Mar 2021

Access to Document

10.1038/s41467-021-21669-4Licence: Creative Commons: Attribution (CC-BY)

BarranEtalNC2021MetabolomicsOfSebumRevealsLipidDysregulationInParkinson’sDiseaseFinal published version, 1.16 MBLicence: Creative Commons: Attribution (CC-BY)

Cite this

@article{89855336b48c4290ac4413305dc28185,

title = "Metabolomics of sebum reveals lipid dysregulation in Parkinson{\textquoteright}s disease",

abstract = "Parkinson{\textquoteright}s disease (PD) is a progressive neurodegenerative disorder, which is characterised by degeneration of distinct neuronal populations, including dopaminergic neurons of the substantia nigra. Here, we use a metabolomics profiling approach to identify changes to lipids in PD observed in sebum, a non-invasively available biofluid. We used liquid chromatography mass spectrometry (LC-MS) to analyse 274 samples from participants (80 drug na{\"i}ve PD,138 medicated PD and 56 well matched control subjects) and detected metabolites that could predict PD phenotype. Pathway enrichment analysis shows alterations in lipid metabolism related to the carnitine shuttle, sphingolipid metabolism, arachidonic acid metabolism and fatty acid biosynthesis. This study shows sebum can be used to identify potential biomarkers for PD.",

author = "Eleanor Sinclair and Trivedi, {Drupad K.} and Depanjan Sarkar and Caitlin Walton-Doyle and Joy Milne and Tilo Kunath and Rijs, {Anouk M.} and {De Bie}, {Rob M. A.} and Royston Goodacre and Monty Silverdale and Perdita Barran",

year = "2021",

month = mar,

day = "11",

doi = "10.1038/s41467-021-21669-4",

language = "English",

volume = "12",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Metabolomics of sebum reveals lipid dysregulation in Parkinson’s disease

AU - Sinclair, Eleanor

AU - Trivedi, Drupad K.

AU - Sarkar, Depanjan

AU - Walton-Doyle, Caitlin

AU - Milne, Joy

AU - Kunath, Tilo

AU - Rijs, Anouk M.

AU - De Bie, Rob M. A.

AU - Goodacre, Royston

AU - Silverdale, Monty

AU - Barran, Perdita

PY - 2021/3/11

Y1 - 2021/3/11

N2 - Parkinson’s disease (PD) is a progressive neurodegenerative disorder, which is characterised by degeneration of distinct neuronal populations, including dopaminergic neurons of the substantia nigra. Here, we use a metabolomics profiling approach to identify changes to lipids in PD observed in sebum, a non-invasively available biofluid. We used liquid chromatography mass spectrometry (LC-MS) to analyse 274 samples from participants (80 drug naïve PD,138 medicated PD and 56 well matched control subjects) and detected metabolites that could predict PD phenotype. Pathway enrichment analysis shows alterations in lipid metabolism related to the carnitine shuttle, sphingolipid metabolism, arachidonic acid metabolism and fatty acid biosynthesis. This study shows sebum can be used to identify potential biomarkers for PD.

AB - Parkinson’s disease (PD) is a progressive neurodegenerative disorder, which is characterised by degeneration of distinct neuronal populations, including dopaminergic neurons of the substantia nigra. Here, we use a metabolomics profiling approach to identify changes to lipids in PD observed in sebum, a non-invasively available biofluid. We used liquid chromatography mass spectrometry (LC-MS) to analyse 274 samples from participants (80 drug naïve PD,138 medicated PD and 56 well matched control subjects) and detected metabolites that could predict PD phenotype. Pathway enrichment analysis shows alterations in lipid metabolism related to the carnitine shuttle, sphingolipid metabolism, arachidonic acid metabolism and fatty acid biosynthesis. This study shows sebum can be used to identify potential biomarkers for PD.

U2 - 10.1038/s41467-021-21669-4

DO - 10.1038/s41467-021-21669-4

M3 - Article

SN - 2041-1723

VL - 12

JO - Nature Communications

JF - Nature Communications

IS - 1

M1 - 1592

ER -

Metabolomics of sebum reveals lipid dysregulation in Parkinson’s disease

Abstract / Description of output

Access to Document

Fingerprint

Cite this